6 facts to know about the iconic Goodyear Blimp which turns 100 this week
The iconic Goodyear airships are taking a victory lap over the skies of an Ohio city this week.
The Akron-based tire company is celebrating the 100th anniversary of 'Pilgrim,' its first blimp to take flight just outside of the city on June 3, 1925.
Goodyear began experimenting with vessels that would be lighter than aircraft in the early 1900s, and the dirigibles have since become a lasting and iconic symbol of the corporate brand. For some, it evokes nostalgia, while for others it offers a glimpse into a larger-than-life part of advertisement history.
Here is a by-the-numbers look at Goodyear airships over time:
1910
Goodyear establishes an Aeronautics Department to build lighter-than-air aircrafts, and by 1912 the company had built its first balloon.
In 1930, the 'Defender' blimp became the first airship in the world to carry a lit neon sign so the company's name could be seen after dark.
Goodyear began making airships for the U.S. Navy in 1917, and its first blimp — the first commercial non-rigid airship flown using helium — launched years later, becoming a marketing tool.
From 1942 to 1944, the company built more than 150 airships for the Navy to serve in World War II, flying patrol over warships on the seas with zero reported loss of ships when a blimp was on watch.
New Year's Day 1955
The Goodyear Blimp has been a regular at major sporting events since flying above the 1955 Rose Bowl. A few years later, it became a service vehicle for television coverage while simultaneously functioning as a highly visible advertising platform.
Since that time, blimps have undergone wholesale changes and improved dramatically: steering technology; safety innovations; high-definition cameras; aerial views captured with specialized systems that compensate for movement during filming, resulting in stable and smooth footage footage; and much quieter rides thanks to relocated engines and propellers.
4 blimps
There currently are four Goodyear Blimps — the three in the U.S. and one in Friedrichshafen, Germany.
Today's Goodyear Blimps are semi-rigid dirigibles, meaning they have an internal frame as compared to previous eras of blimps that could be fully deflated. In 2014, Goodyear transitioned to the New Technology semi-rigid airship platform designed to allow for improved maneuverability and speed.
246 feet
The Goodyear Blimp is 246 feet long (75 meters), which would cover about 80% of a football field. It is 58 feet (18 meters) high and holds three Olympic-sized swimming pools' worth of helium.
Goodyear gets helium for its blimps from multiple sources. Because helium is a finite resource, the company purifies its helium every six to eight weeks to extend its life.
The blimp travels more than 100 days per year, with trips ranging anywhere from three days to three weeks. A crew of nearly 20 people travel with the airship whenever it is touring. Today's Goodyear Blimps fly between 1,000 and 1,500 feet (305 meters and 457 meters) in the air and travel at speeds up to 73 miles per hour (117 kilometers per hour).
10 blimp pilots
There currently are fewer blimp pilots in the world than astronauts, according to Goodyear, which has 10 full-time pilots. To serve in that job, you must have a commercial pilot license followed by approximately 250 hours of training to earn an additional lighter-than-air airship rating from the Federal Aviation Administration.
2,500 and 500,000
The blimp has covered more than 2,500 events and taken more than 500,000 passengers for rides, according to Goodyear. Former President Ronald Reagan might be the most famous passenger, but it was rapper Ice Cube who raised the blimp's street cred when he included a line about it in his 1992 song titled 'It Was A Good Day.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Yahoo
25 minutes ago
- Yahoo
PGA Tour Sends Strong Scottie Scheffler Message on Saturday
PGA Tour Sends Strong Scottie Scheffler Message on Saturday originally appeared on Athlon Sports. The PGA Tour celebrated Scottie Scheffler in style on Saturday, honoring the world No. 1 golfer on his birthday with an Instagram post from @pgatour showcasing his top 10 career shots. Advertisement The post, shared earlier today, serves as a tribute to his remarkable journey, timed perfectly as fans and the Tour alike mark his special day. This gesture underscores Scheffler's status as a golfing icon and the Tour's commitment to celebrating its brightest stars. The post highlights iconic moments, including his hole-in-one at the 2023 Charles Schwab Challenge and his remarkable eagle hole-out at the 2024 Players Championship. These shots reflect the precision and power that have defined his rise, with three wins in his last five starts this season, including a victory at the 2025 PGA Championship. Scottie Scheffler plays his shot from the tenth tee during the first round.© Charles LeClaire-Imagn Images The birthday tribute aligns with Scheffler being in contention at the Travelers Championship this weekend, tying for the 36-hole lead with a score of nine under par. Advertisement This celebration sends a clear message: Scheffler, at 29, is the Tour's present and future and will continue to dominate a majority of the tournaments he plays in. With competitors like Tommy Fleetwood and Justin Thomas challenging his lead, his career highlights remind fans of his consistency and clutch performances. The post has sparked excitement, reinforcing the Tour's intent to honor excellence while hyping its toughest course setups and merit-based finales. For golf enthusiasts, it's a fitting birthday salute to a player redefining the sport. Related: PGA Tour Teases Scottie Scheffler, Justin Thomas Pairing at Travelers Championship This story was originally reported by Athlon Sports on Jun 21, 2025, where it first appeared.
